Julia Lainster

Julia Lainster

HealthTech Solutions Expert
Julia Lainster is an expert in Healthtech with a focus on electronic health records, interoperability standards, and cybersecurity. Her content is geared toward industry leaders and organizations seeking to leverage technology to improve efficiency, accuracy, and security in healthcare delivery. Julia aims to drive digital transformation and innovation in Healthtech.
Can Blinatumomab Transform Pediatric Cancer Treatment Outcomes?
Research & Development Can Blinatumomab Transform Pediatric Cancer Treatment Outcomes?

In recent years, significant advancements have been made in treating pediatric acute lymphocytic leukemia (B-ALL) through combining traditional chemotherapy with innovative drugs like blinatumomab. This blend of treatments, examined in a clinical trial, has shown promising results, particularly in

Can SBRT and Sorafenib Improve Survival in Advanced Liver Cancer?
Research & Development Can SBRT and Sorafenib Improve Survival in Advanced Liver Cancer?

The fight against hepatocellular carcinoma (HCC) has seen a significant breakthrough with the release of new findings from the NRG-RTOG 1112 Phase III clinical study. This study explored the effects of adding stereotactic body radiotherapy (SBRT) to the existing systemic therapy with sorafenib for

How Does Amira Software 2024.2 Revolutionize Image Analysis?
Tech & Innovation How Does Amira Software 2024.2 Revolutionize Image Analysis?

The release of Thermo Scientific™ Amira™ Software Version 2024.2 marks a significant milestone in the field of image analysis, particularly for cellular ultrastructure analysis. This new version introduces a suite of advanced tools and features designed to enhance precision, efficiency, and overall

Can Existing Drugs Offer Hope for Ichthyosis Patients Seeking Relief?
Research & Development Can Existing Drugs Offer Hope for Ichthyosis Patients Seeking Relief?

Ichthyosis, a rare genetic skin disorder, presents significant daily challenges for those affected, compelling them to adhere to labor-intensive skincare routines. Unfortunately, this debilitating condition has not captured major pharmaceutical interest, leaving dedicated dermatologists to

Factors Influencing Participation in COVID-19 Vaccine Trials
Research & Development Factors Influencing Participation in COVID-19 Vaccine Trials

The COVID-19 pandemic presented a global challenge, with governments and health institutions striving to contain the virus amid misinformation and rapid transmission. One pivotal approach was the development of various COVID-19 vaccine trials, employing adaptive methods to expedite recruitment

Does 5-FU Fight Cancer by Targeting RNA Instead of DNA?
Research & Development Does 5-FU Fight Cancer by Targeting RNA Instead of DNA?

5-Fluorouracil (5-FU) has been a cornerstone in cancer treatment for decades, primarily believed to work by damaging DNA and preventing cancer cells from replicating. However, recent research suggests that 5-FU's primary mechanism of action may be through targeting RNA, particularly ribosomal

Can Genetic Insights Improve Treatment for Cryptococcosis Infections?
Research & Development Can Genetic Insights Improve Treatment for Cryptococcosis Infections?

Cryptococcus neoformans infections often pose a significant threat to individuals with weakened immune systems, such as those with HIV/AIDS or organ transplant recipients. These infections can lead to cryptococcosis, a severe condition that initially affects the lungs and may spread to the brain,

Key Developments in Pharma: Gilead, Bristol Myers, Boundless Bio, Lonza
Management & Regulatory Key Developments in Pharma: Gilead, Bristol Myers, Boundless Bio, Lonza

The pharmaceutical and biotechnology sectors are witnessing a whirlwind of significant developments, from legal disputes over acquisition terms to pivotal personnel changes and strategic restructuring initiatives. These shifts are emblematic of an industry in constant evolution, driven by

NICE Approves Neuraxpharm's Ublituximab for RRMS Treatment in the UK
Research & Development NICE Approves Neuraxpharm's Ublituximab for RRMS Treatment in the UK

The recent endorsement of Neuraxpharm's ublituximab (BRIUMVI®) by the National Institute for Health and Care Excellence (NICE) marks a significant step forward in the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval is a notable accomplishment for the European

Study Links Ultra-Processed Foods to Increased Risk of Colorectal Cancer
Research & Development Study Links Ultra-Processed Foods to Increased Risk of Colorectal Cancer

A recent study spearheaded by University of South Florida (USF) Health researchers, in collaboration with TGH Cancer Institute, has unveiled a potential link between ultra-processed foods and an increased risk of colorectal cancer. Researchers highlighted how these foods may contribute to chronic

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later